Here are the 10-K annual reports from Ardelyx, Inc. (ARDX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ARDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARDX filings page.
Ardelyx, Inc. filed its Form 10-K describing a commercial-stage biopharma business built around tenapanor, marketed as IBSRELA for IBS‑C and XPHOZAH for dialysis patients with hyperphosphatemia. The company is expanding tenapanor into chronic idiopathic constipation through the Phase 3 ACCEL trial and advancing a next‑generation NHE3 inhibitor, RDX10531.
The filing highlights that XPHOZAH’s inclusion in the ESRD Prospective Payment System on January 1, 2025 eliminated Medicare Part D coverage, causing a negative and material impact on 2025 XPHOZAH revenue and pointing to slower future growth. Ardelyx reports cash, cash equivalents and short‑term investments of $264.7 million and $200 million of term debt outstanding as of December 31, 2025, plus an unused at‑the‑market equity program of up to $100 million. Management emphasizes ongoing losses since inception, reliance on growing IBSRELA and XPHOZAH sales, and potential need for additional financing while it continues to invest in commercialization and pipeline development.